...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian Journal of Veterinary Research >Evidence that antibodies against recombinant SnSAG1 of Sarcocystis neurona merozoites are involved in infection and immunity in equine protozoal myeloencephalitis
【24h】

Evidence that antibodies against recombinant SnSAG1 of Sarcocystis neurona merozoites are involved in infection and immunity in equine protozoal myeloencephalitis

机译：马肉原生动物脊髓性脑炎的抗结节虫神经节裂殖子重组SnSAG1抗体参与感染和免疫的证据

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sarcocystis neurona is the principal etiologic agent of equine protozoal myeloencephalitis (EPM). An immunodominant protein of S. neurona, SnSAG-1, is expressed by the majority of S. neurona merozoites isolated from spinal tissues of horses diagnosed with EPM and may be a candidate for diagnostic tests and prophylaxis for EPM. Five horses were vaccinated with adjuvanted recombinant SnSAG1 (rSnSAG1) and 5 control (sham vaccinated) horses were vaccinated with adjuvant only. Serum was evaluated pre- and post-vaccination, prior to challenge, for antibodies against rSnSAG1 and inhibitory effects on the infectivity of S. neurona by an in vitro serum neutralization assay. The effect of vaccination with rSnSAG1 on in vivo infection by S. neurona was evaluated by challenging all the horses with S. neurona merozoites. Blinded daily examinations and 4 blinded neurological examinations were used to evaluate the presence of clinical signs of EPM. The 5 vaccinated horses developed serum and cerebrospinal fluid (CSF) titers of SnSAG1, detected by enzyme-linked immunosorbent assay (ELISA), post-vaccination. Post-vaccination serum from vaccinated horses was found to have an inhibitory effect on merozoites, demonstrated by in vitro bioassay. Following the challenge, the 5 control horses displayed clinical signs of EPM, including ataxia. While 4 of the 5 vaccinated horses did not become ataxic. One rSnSAG-1 vaccinated horse showed paresis in 1 limb with muscle atrophy. All horses showed mild, transient, cranial nerve deficits; however, disease did not progress to ataxia in rSnSAG-1 vaccinated horses. The study showed that vaccination with rSnSAG-1 produced antibodies in horses that neutralized merozoites when tested by in vitro culture and significantly reduced clinical signs demonstrated by in vivo challenge.
机译：神经肉囊藻是马原生动物脊髓性脑炎（EPM）的主要病因。从诊断为EPM的马的脊柱组织中分离出的大多数S. Neurona裂殖子表达S. Neurona的一种免疫优势蛋白，它可能是诊断测试和预防EPM的候选药物。五匹马用佐剂的重组SnSAG1（rSnSAG1）进行了疫苗接种，而5匹对照（假疫苗）的马只用佐剂进行了疫苗接种。通过体外血清中和试验，在接种之前和之后，在接种之前和之后评估血清中抗rSnSAG1的抗体和对神经链球菌感染性的抑制作用。通过用神经链球菌裂殖子攻击所有马，评估了rSnSAG1疫苗接种对体内感染链球菌的效果。每天进行盲法检查和4次神经盲检查，以评估EPM的临床体征。接种疫苗后，这五匹接种疫苗的马的血清和脑脊液（CSF）滴度为SnSAG1，通过酶联免疫吸附测定（ELISA）检测。通过体外生物测定证明，已接种马匹的疫苗接种后血清对裂殖子有抑制作用。挑战后，5匹对照马表现出EPM的临床体征，包括共济失调。虽然在5匹接种疫苗的马匹中有4匹没有发生共济失调。一匹接种rSnSAG-1的马在1条肢体中出现轻瘫，出现肌肉萎缩。所有马匹均表现出轻度，短暂，颅神经缺损。然而，在rSnSAG-1疫苗接种的马中，疾病并未发展为共济失调。该研究表明，用rSnSAG-1进行疫苗接种可在马中产生抗体，这些马在通过体外培养进行测试时会中和裂殖子，并显着降低了体内攻击证明的临床体征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号